Brokerages Anticipate Evotec AG (EVTCY) to Post $0.12 EPS

Evotec AG (NASDAQ:EVTCY) has earned an average broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. Evotec AG’s rating score has improved by 33.3% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Zacks has also given Evotec AG an industry rank of 154 out of 265 based on the ratings given to related companies.

Several analysts have issued reports on EVTCY shares. Zacks Investment Research cut Evotec AG from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. DZ Bank AG restated a “sell” rating on shares of Evotec AG in a report on Thursday, August 17th.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/17/brokerages-anticipate-evotec-ag-evtcy-to-post-0-12-eps.html.

Evotec AG (NASDAQ EVTCY) opened at 51.15 on Tuesday. The company has a 50 day moving average of $45.01 and a 200-day moving average of $32.44. The stock has a market capitalization of $3.74 billion and a price-to-earnings ratio of 85.82. Evotec AG has a 12-month low of $10.82 and a 12-month high of $52.82.

Evotec AG (NASDAQ:EVTCY) last issued its quarterly earnings results on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). The company had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zac

Zacks has also given Evotec AG an industry rank of 154 out of 265 based on the ratings given to related companies.

Several analysts have issued reports on EVTCY shares. Zacks Investment Research cut Evotec AG from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. DZ Bank AG restated a “sell” rating on shares of Evotec AG in a report on Thursday, August 17th.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/17/brokerages-anticipate-evotec-ag-evtcy-to-post-0-12-eps.html.

Evotec AG (NASDAQ EVTCY) opened at 51.15 on Tuesday. The company has a 50 day moving average of $45.01 and a 200-day moving average of $32.44. The stock has a market capitalization of $3.74 billion and a price-to-earnings ratio of 85.82. Evotec AG has a 12-month low of $10.82 and a 12-month high of $52.82.

Evotec AG (NASDAQ:EVTCY) last issued its quarterly earnings results on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). The company had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply